Abstract: Alteplase (recombinant tissue plasminogen activator) has been used in the treatment of acute ischemic stroke for 10 years. The application of this drug is considered safe and effective. However, alteplase is also associated with side effects. The author is reporting on an unusual side effect of angioedema that is triggered by alteplase. Angioedema occurs through alteplase according to this study at a frequency of 5.88% (95% confidence interval: 0.98% to 28.76%). In this case immunoglobulin G was slightly increased. The relative risk to get an angioedema compared between the two genders is elevated in men 3.3 (95% confidence interval: 0.15% to 71.90%; P = 0.4423), who were 3.3 times more likely to suffer than women. The use of angiotensin-converting-enzyme (ACE) inhibitors is considered a possible risk factor for the occurrence of angioedema with concomitant administration of tissue plasminogen activator. The angioedema may occur with use of alteplase at any time, so treatment with this drug must always be carried out in intensive care and doctors must be ready for intubation if necessary.
展开▼
机译：摘要：阿替普酶（重组组织纤溶酶原激活物）已用于治疗急性缺血性卒中已有10年的历史。该药物的应用被认为是安全有效的。但是，阿替普酶也与副作用有关。作者报告了由阿替普酶引起的血管性水肿的异常副作用。根据这项研究，通过阿替普酶发生血管性水肿的发生率为5.88％（95％置信区间：0.98％至28.76％）。在这种情况下，免疫球蛋白G略有增加。两种性别的人相比，发生血管性水肿的相对风险在男性中升高了3.3（95％的置信区间：0.15％至71.90％; P = 0.4423），她们患病的可能性是女性的3.3倍。血管紧张素转换酶（ACE）抑制剂的使用被认为是伴随组织纤溶酶原激活物给药而发生血管性水肿的可能危险因素。任何时候使用阿替普酶都可能发生血管性水肿，因此必须始终在重症监护下进行该药物的治疗，必要时医生必须准备插管。
展开▼
